Free Trial
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

ACADIA Pharmaceuticals logo
$25.74 +0.96 (+3.87%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$25.58 -0.15 (-0.60%)
As of 08/22/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

Key Stats

Today's Range
$24.90
$25.81
50-Day Range
$20.88
$25.74
52-Week Range
$13.40
$25.88
Volume
3.42 million shs
Average Volume
1.84 million shs
Market Capitalization
$4.34 billion
P/E Ratio
19.35
Dividend Yield
N/A
Price Target
$28.88
Consensus Rating
Moderate Buy

Company Overview

ACADIA Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

ACAD MarketRank™: 

ACADIA Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 225th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    ACADIA Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ACADIA Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ACADIA Pharmaceuticals is 19.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ACADIA Pharmaceuticals is 19.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.10.

  • Price to Earnings Growth Ratio

    ACADIA Pharmaceuticals has a PEG Ratio of 6.31. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    ACADIA Pharmaceuticals has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ACADIA Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.89% of the float of ACADIA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in ACADIA Pharmaceuticals has recently decreased by 3.92%, indicating that investor sentiment is improving.
  • Dividend Yield

    ACADIA Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ACADIA Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.89% of the float of ACADIA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in ACADIA Pharmaceuticals has recently decreased by 3.92%, indicating that investor sentiment is improving.
  • News Sentiment

    ACADIA Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for ACADIA Pharmaceuticals this week, compared to 10 articles on an average week.
  • Search Interest

    Only 4 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $868,594.00 in company stock.

  • Percentage Held by Insiders

    26.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ACADIA Pharmaceuticals' insider trading history.
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

The Secret E.I. Project No One’s Talking About… Yet
It took Netflix 3.5 years to reach 1 million users. Twitter? Two years. Facebook? Ten months. ChatGPT? Just 5 days. Now, the next evolution of AI is coming—and it’s happening fast. Known as embodied intelligence (E.I.), this breakthrough merges AI with robotics to create advanced machines: from robot caregivers to autonomous soldiers. Top researchers from around the globe are quietly collaborating on a massive E.I. project set to launch within 90 days.tc pixel
High Growth Tech Stocks To Watch In The US August 2025
See More Headlines

ACAD Stock Analysis - Frequently Asked Questions

ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of the year. Since then, ACAD shares have increased by 40.3% and is now trading at $25.74.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The company's revenue was up 9.4% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of ACADIA Pharmaceuticals include State Street Corp (3.66%), Geode Capital Management LLC (1.81%), First Trust Advisors LP (1.44%) and Marshall Wace LLP (1.17%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Brendan Teehan, Srdjan R Stankovic, Austin D Kim, Mark C Schneyer, James Kihara, Elizabeth A Garofalo and Laura Brege.
View institutional ownership trends
.

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/06/2025
Today
8/22/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACAD
CIK
1070494
Employees
510
Year Founded
N/A

Price Target and Rating

High Price Target
$40.00
Low Price Target
$17.00
Potential Upside/Downside
+12.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.33
Trailing P/E Ratio
19.35
Forward P/E Ratio
36.77
P/E Growth
6.31
Net Income
$226.45 million
Net Margins
21.80%
Pretax Margin
26.29%
Return on Equity
14.69%
Return on Assets
9.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.91
Quick Ratio
2.83

Sales & Book Value

Annual Sales
$957.80 million
Price / Sales
4.53
Cash Flow
$0.73 per share
Price / Cash Flow
35.16
Book Value
$4.87 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
168,710,000
Free Float
124,003,000
Market Cap
$4.34 billion
Optionable
Optionable
Beta
0.70

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ACAD) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners